ASX Share rice
Thu 06 May 2021 - 08:15:am (Sydney)

ATH Share Price

ALTERITY THERAPEUTICS LIMITEDATHPharmaceuticals, Biotechnology & Life Sciences

ATH Company Information

Name:

Alterity Therapeutics Limited

Sector:

Healthcare

Industry:

Biotechnology

Address:

460 Bourke Street Melbourne VIC Australia 3000

Phone:

61 3 9349 4906

Full Time Employees:

12

Co-Founder & Non-Exec. Chairman:

Mr. Geoffrey Paul Kempler B.Sc., B.Sc

CEO, Chief Medical Officer & Sr. VP of Clinical Devel.:

Dr. David A. Stamler

Chief Financial Officer:

Ms. Kathryn J. E. Andrews

Chief Scientific Advisor and Member of R&D Advisory Board:

Dr. Rudolph Emile Tanzi

Chief Medical Advisor:

Dr. Steven D. Targum

Head of Research:

Dr. Robert Cherny

Company Sec.:

Mr. Phillip Allen Hains

Company Overview:

Alterity Therapeutics Limited researches and develops therapeutic drugs for the treatment of Parkinsonian's disease and other neurodegenerative diseases in Australia. The company's lead drug candidates is ATH434 that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing PBT2 for used as an antimicrobial agent. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. The company was founded in 1997 and is based in Melbourne, Australia.

ATH Share Price Information

Shares Issued:

2.08B

Market Capitalisation:

$60.44M

Revenue (TTM):

$28.15K

Earnings per Share:

$-0.02

Operating Margin (TTM):

$-564.94

Return On Assets (TTM):

$-0.38

Return On Equity (TTM):

$-0.72

Quarterly Revenue Growth (YOY):

0.015

Gross Profit(TTM):

$-352,922

Diluted Earnings Per Share (TTM):

$-0.015

ATH CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$-16,744

Change To Liabilities:

$-648,570

Total Cashflow From Investing Activities:

$-16,744

Net Borrowings:

$-89,241

Net Income:

$-13,456,800

Total Cash From Operating Activities:

$-9,431,122

Depreciation:

$112.43K

Dividends Paid:

$0

Change To Account Receivables:

$4.77M

Sale Purchase Of Stock:

$4.36M

Capital Expenditures:

$16.74K

ATH Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-13,456,800

Net Income:

$-13,456,800

Operating Income:

$-13,789,850

Other Operating Expenses:

$44.22K

Total Revenue:

$17.12K

Total Operating Expenses:

$10.07M

ATH Balance Sheet

Balance Sheet Date:

2020-06-30

Total Liabilities:

$2.76M

Total Stockholder Equity:

$7.15M

Other Current Liabilities:

$10.96K

Total Assets:

$9.91M

Common Stock:

$160.70M

Other Current Assets:

$10.25K

Retained Earnings:

$-154,419,061

Other Liabilities:

$41.51K

Cash:

$192.71K

Total Current Liabilities:

$2.71M

Property - Plant & Equipment:

$71.37K

Net Tangible Assets:

$7.15M

Total Current Assets:

$9.84M

Net Receivables:

$61.32K

Short-Term Investments:

$71.37K

Accounts Payable:

$0.95M

Short-Term Investments:

$71.37

Non Current Liabilities Total:

$42.38K

ATH Share Price History

ATH News

29 Apr, 2021
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31 March 2021 (Q3 FY21).
21 Apr, 2021
Alterity Therapeutics (NASDAQ: ATHE) has announced the presentation of expanded animal data to support the commercialization of its lead compound ATH434 in development to treat Parkinsonian disorders. Data were presented at the American Academy of Neurology virtual annual meeting. The data from an animal model of Multiple System Atrophy (MSA) independently confirm and extend previous findings demonstrating that ATH434 reduces α-synuclein pathology, preserves neurons, and improves motor function. MSA is a rare neurodegenerative disorder characterized by autonomic dysfunction, tremors, slow movement, muscle rigidity, and postural instability. The new data indicate that ATH434 preserves neurons not only in the substantia nigra, a main area of pathology in Parkinson's disease but also in the striatum, a region of the brain that integrates information from the cortex and substantia nigra to achieve fine motor control. The study also showed that ATH434 led to reductions in glial cell inclusions, comprised of aggregated α-synuclein, and levels of the toxic form of α-synuclein, both of which are pathological features of MSA. Price Action: ATHE shares are up 22.4% at $1.53 in premarket trading on the last check Wednesday. See more from BenzingaClick here for options trades from BenzingaBrii Biosciences, Vir Biotech, VBI Vaccines Start Combination Therapy Hepatitis B StudyTrevena's TRV027 Included In Global COVID-19 Study© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced an oral presentation of expanded animal data to support the commercialisation of its lead compound ATH434 in clinical development for the treatment of Parkinsonian disorders, at the American Academy of Neurology (AAN) virtual annual meeting.
26 Feb, 2021
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), will present at the upcoming 7th International Congress of Multiple System Atrophy (MSA2021), to be held in a virtual format from February 26-27, 2021.
09 Feb, 2021
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the award of a grant from The Michael J. Fox Foundation for Parkinson's Research to determine optimal dosing of its lead drug candidate ATH434 for Parkinson's disease (PD) based on imaging of brain iron.
07 Jan, 2021
13:00
Yahoo! Finance
The Board of Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") is pleased to announce the appointment of Dr David Stamler to the role of Chief Executive Office effective immediately.
21 Dec, 2020
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced it has been granted a licence by UniQuest, the commercialisation company of The University of Queensland (UQ), to novel zinc ionophore technology to combat antimicrobial resistance in superbugs.
09 Dec, 2020
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
16 Nov, 2020
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has today announced the allowance of a new composition of matter patent by the United States Patent and Trademark Office (USPTO). The new patent is the product of in-house discovery research and is central to Alterity's next generation drug development portfolio focussed on neurodegenerative diseases.
27 Oct, 2020
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced it has commenced enrolling patients with Multiple System Atrophy (MSA) in its bioMUSE Study in the United States.
05 Aug, 2020
Alterity Therapeutics (NASDAQ: ATHE) shares are trading lower on Wednesday.This is a potential sell-off after the stock increased over 200% yesterday following the company announcing it will present at two upcoming conferences and is expected to report positive data for its treatment for Parkinson's Disorder MSA.Alterity Therapeutics is engaged in research collaboration with Takeda for the treatment of Parkinson's disease gastrointestinal neuropathology. The company's lead drug candidate-PBT2 is being developed for the treatment of Alzheimer's and Huntington's diseases. It has also advanced a drug candidate for Parkinson's disease and other movement disorders (PBT434) and brain cancer (PBT519), which are in preclinical toxicology testing.Alterity Therapeutics shares were trading down 15.47% to $2.90 at time of publication on Wednesday. The stock has a 52-week high of $5.15 and a 52-week low of 28 cents.See more from Benzinga * Why Alterity's Stock Is Trading Higher Today * Why Alterity Therapeutics Stock Is Trading Higher Today(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
04 Aug, 2020
The shares of Alterity Therapeutics Ltd. (NASDAQ: ATHE) advanced in the after-hours session trading in New York on Monday and in the regular session in Sydney on Tuesday.What Happened: The surge came as Alterity Therapeutics reported positive data from an animal testing of ATH434 — its leading drug candidate for Multiple System Atrophy, a Parkinsonian disorder.The new data "independently confirm and extend previous findings demonstrating that ATH434 reduces α-synuclein pathology, preserves neurons, and improves motor performance," Alterity Therapeutics noted.Why It Matters: The Melbourne-based pharmaceutical company in June said it had reached an agreement with the United States Food and Drug Administration on the non-clinical investigations required to support the second phase of its clinical trial of ATH434.The FDA had also agreed on the company's design for the Phase 2 study, it claimed.What's Next: Alterity Therapeutics noted that the data from the latest study will be presented at the 2020 International Congress of Parkinson's Disease and Movement Disorders in September and at the American Neurological Association's 2020 Annual Meeting in October.Price Action: The company's shares closed 38.24% up at $0.034 in Sydney on Tuesday, with an intraday high of $0.041.Alterity Therapeutics shares closed 10.37% higher at $1.49 in the after-hours session in New York on Monday. See more from Benzinga * Prescription Drug Prices Tracker, Telehealth Platform GoodRx Files For IPO: Report * Huawei Becomes The World's Largest Smartphone Supplier As China Sales Remain High During Pandemic * Tesla Under Probe In South Korea For Supposed Issues With Autopilot, Other Braking, Steering Systems(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") today announced that new clinical and experimental pharmacology data for its lead drug candidate ATH434 (formerly PBT434) has been selected for presentation at the 2020 International Congress of Parkinson's Disease and Movement Disorders (MDS 2020) and the American Neurological Association's 2020 Annual Meeting (ANA 2020).
30 Jul, 2020
Alterity Therapeutics Limited (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") releases its Appendix 4C Quarterly Cash Flow Report and update on company activities for the quarter ending 31 July 2020 (Q4 FY20).
30 Jun, 2020
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") is pleased to announce that it has received guidance from the US Food and Drug Administration (FDA) in relation to the development pathway for ATH434 (previously PBT434), the company's lead compound for the treatment of Multiple System Atrophy (MSA), a Parkinsonian disorder.
21 May, 2020
Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company") has presented data on ATH434 (formerly PBT434) for the treatment of Multiple System Atrophy at the American Academy of Neurology (AAN) virtual meeting.